



IFW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/827,514
	Filing Date	April 19, 2004
	First Named Inventor	Bolin
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	21099 US1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks USPTO FORM 1449; REFERENCES		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Eileen M. Ebel	
Signature		
Date	July 22, 2004	

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Eileen M. Ebel		
Signature		Date	July 22, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

David R. Bolin, et. al.

Group:

Serial No. 10/827,514, filed April 19, 2004

Examiner:

Docket No. 21099 US1

For: GLUTAMINE FRUCTOSE-Y-PHOSPHATE AMIDOTRANSFERASE (GFAT) INHIBITORS

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110

July 22, 2004

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents B1 – B3 and C1 – C12 listed on Form PTO-1449 are enclosed.


Documents B1 and B2, which are not written in the English language, are abstracted in Documents B1(a) and B2(a).

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/827,514
Filed: April 19, 2004

Since the Information Disclosure Statement is submitted before receipt of the first Office Action on the merits for the above application, it is believed that no fee is due. If any fees are owing, please charge our deposit account 08-2525.

Respectfully submitted,



Attorney for Applicant(s)
Eileen M. Ebel
(Reg. No. 37,316)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-4391
Telefax: (973) 235-2363

144033

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Complete if Known	
				Application Number	10/827,514
				Filing Date	April 19, 2004
				First Name Inventor	Bolin
				Group Art Unit	
				Examiner Name	
Sheet	2	Of	2	Attorney Docket Number	21099 US1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	ANSELM, ELSE, et. al., "Selective inhibition of calcium entry induced by benzylisoquinolines in rat smooth muscle", J. Pharm. Pharmacol. (1992) 44(4), 337-343	
	C2	M.A. BADET-DENISOT, et. al., Bioorg. Med. Chem. Letters, 5, 815-820 (1995)	
	C3	S.L. BEARNE, J. Biol. Chem., 271, 3052-3057 (1996)	
	C4	S.L. BEARNE, et. al., Biochem., 34, 11515-11520 (1995)	
	C5	F. BISTER-MIEL, et. al., Plantes Medicinales et Phytotherapie (1986), Tome XX, n°1, p. 3-7	
	C6	CHEN CHEN, et. al., J. Med. Chem. (2001) 44, 4001-4010	
	C7	H. CHMARA, J. Gen. Microbiol., 131, 265-271 (1985)	
	C8	MARKWARDT, FRITZ, et. al., "Influence of 6,7-dimethoxyisoquinoline derivatives on the function of thrombocytes" Acta Biologica et Medica Germanica (1969) 23(2), 295-306	
	C9	F. MASSIERE, et. al., J. Amer. Chem. Soc., 119, 5748-5749 (1997)	
	C10	S. MILEWSKI, et. al., Biochim. Biophys. Acta, 1115, 225-229 (1992)	
	C11	E. POSTAIRE, et. al., Ann. Pharmaceutiques Francaises (1985), 43, n°6, pp. 547-556	
	C12	D. WALTEROVA, et. al., Collection Czechoslov. Chem. Commun, (1980), 45, pp. 956-965	
Examiner Signature	DATE CONSIDERED		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation or abstract is attached.